Global Blood Therapeutics has shared updated data on the sickle cell disease trial it hopes will secure FDA approval of voxelotor. The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo, resulting in the trial hitting its primary endpoint.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,